Abstract
Introduction: Primary hemophagocytic lymphohistiocytosis (HLH) is a hyper-inflammatory disorder characterized by dysregulation of inflammatory cells and cytokine signaling. Although first-line treatment consisting of immunosuppressive therapy and allogeneic hematopoietic cell transplantation (HCT) is often curative, it remains unknown whether any effective therapies exist for disease relapse/progression after HCT. Case Presentation: Here we present a case of a 29-year-old male with primary HLH who failed HLH-94 protocol and subsequently underwent myeloablative HCT. Disease relapse occurred at 9 months following HCT, and donor lymphocyte infusion (DLI) was initiated as salvage therapy. The patient subsequently achieved durable long-term disease-free survival following a DLI, without significant treatment-related complications. Conclusion: To our knowledge, this represents the first case demonstrating the efficacy of DLI for relapsed primary HLH.
Journal Section:
Case Report
References
1.
Janka
GE
. Familial and acquired hemophagocytic lymphohistiocytosis
. Annu Rev Med
. 2012
;63
:233
–46
.2.
Memon
F
, Ahmed
J
, Malik
F
, Ahmad
J
, Memon
DA
. Adult-onset primary hemophagocytic lymphohistiocytosis: reporting a rare case with review of literature
. Cureus
. 2020
;12
(1
):e6723
.3.
Schram
AM
, Comstock
P
, Campo
M
, Gorovets
D
, Mullally
A
, Bodio
K
et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years
. Br J Haematol
. 2016
;172
(3
):412
–9
.4.
Henter
JI
, Horne
A
, Aricó
M
, Egeler
RM
, Filipovich
AH
, Imashuku
S
et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
. Pediatr Blood Cancer
. 2007
;48
(2
):124
–31
.5.
Ouachée-Chardin
M
, Elie
C
, de Saint Basile
G
, Le Deist
F
, Mahlaoui
N
, Picard
C
et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients
. Pediatrics
. 2006
;117
(4
):e743
–50
.6.
Horne
A
, Janka
G
, Maarten Egeler
R
, Gadner
H
, Imashuku
S
, Ladisch
S
et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis
. Br J Haematol
. 2005
;129
(5
):622
–30
.7.
Cesaro
S
, Locatelli
F
, Lanino
E
, Porta
F
, Di Maio
L
, Messina
C
et al. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP)
. Haematologica
. 2008
;93
(11
):1694
–701
.8.
Henter
JI
, Aricò
M
, Egeler
RM
, Elinder
G
, Favara
BE
, Filipovich
AH
et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society
. Med Pediatr Oncol
. 1997
;28
(5
):342
–7
.9.
Marsh
RA
, Vaughn
G
, Kim
MO
, Li
D
, Jodele
S
, Joshi
S
et al. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation
. Blood
. 2010
;116
(26
):5824
–31
.10.
Marsh
RA
, Kim
MO
, Liu
C
, Bellman
D
, Hart
L
, Grimley
M
et al. An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis
. Biol Blood Marrow Transplant
. 2013
;19
(11
):1625
–31
.11.
Marsh
RA
, Jordan
MB
, Filipovich
AH
. Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward
. Br J Haematol
. 2011
;154
(5
):556
–63
.12.
Khanolkar
RA
, Tripathi
G
, Dharmani-Khan
P
, Dabas
R
, Kinzel
M
, Kalra
A
et al. Incomplete chimerism following myeloablative and anti-thymocyte globulin-conditioned hematopoietic cell transplantation is a risk factor for relapse and chronic graft-versus-host disease
. Cytotherapy
. 2022
;24
(12
):1225
–31
.13.
Przepiorka
D
, Weisdorf
D
, Martin
P
, Klingemann
HG
, Beatty
P
, Hows
J
et al. 1994 consensus conference on acute GVHD grading
. Bone Marrow Transplant
. 1995
;15
(6
):825
–8
.14.
Jagasia
MH
, Greinix
HT
, Arora
M
, Williams
KM
, Wolff
D
, Cowen
EW
et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report
. Biol Blood Marrow Transplant
. 2015
;21
(3
):389
401.e1
.15.
Huang
W
, Wang
Y
, Wang
J
, Zhang
J
, Wu
L
, Li
S
et al. Clinical characteristics of 192 adult hemophagocytic lymphohistiocytosis
. Zhonghua Xue Ye Xue Za Zhi
. 2014
;35
(9
):796
–801
.16.
Wang
Y
, Huang
W
, Hu
L
, Cen
X
, Li
L
, Wang
J
et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis
. Blood
. 2015
;126
(19
):2186
–92
.17.
Locatelli
F
, Jordan
MB
, Allen
C
, Cesaro
S
, Rizzari
C
, Rao
A
et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis
. N Engl J Med
. 2020
;382
(19
):1811
–22
.18.
Boonstra
PS
, Ahmed
A
, Merrill
SA
, Wilcox
RA
. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis
. Am J Hematol
. 2021
96
4
E103
5
.19.
Wang
J
, Wang
Z
. Multicenter study of ruxolitinibcombined DEP regimen as a salvage therapy for refractory/relapsed hemophagocytic lymphohistiocytosis
. Blood
. 2019
134
Supplement_1
1042
.20.
Marsh
RA
, Allen
CE
, McClain
KL
, Weinstein
JL
, Kanter
J
, Skiles
J
et al. Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
. Pediatr Blood Cancer
. 2013
;60
(1
):101
–9
.21.
Chang
YJ
, Huang
XJ
. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom
. Blood Rev
. 2013
;27
(1
):55
–62
.22.
Deol
A
, Lum
LG
. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited
. Cancer Treat Rev
. 2010
;36
(7
):528
–38
.23.
Ye
Y
, Yang
L
, Yuan
X
, Huang
H
, Luo
Y
. Optimization of donor lymphocyte infusion for AML relapse after allo-HCT in the era of new drugs and cell engineering
. Front Oncol
. 2021
;11
:790299
.© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.
